KRYS

Krystal Biotech is a commercial-stage gene therapy company developing treatments for serious diseases with high unmet medical need. The company's lead product, Vyjuvek, is the first topical gene therapy approved by the FDA for the treatment of dystrophic epidermolysis bullosa, a rare genetic skin disorder. Krystal's proprietary platform technology enables gene delivery through skin application.